The collaboration is set to begin with a Phase III trial in first-line triple-negative breast cancer, with the partners sharing trial costs while retaining rights to their respective medicines. IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca and Daiichi Sankyo have entered into a … Read the full press release →
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged ADC, antibody-drug conjugate, AstraZeneca, AstraZeneca and Daiichi Sankyo expand ADC combination strategy with Summit’s ivonescimab, AstraZeneca, Daiichi Sankyo and Summit plan Datroway–ivonescimab clinical programme across multiple cancers, breast cancer, Daiichi Sankyo, datopotamab deruxtecan, Datroway, Datroway and ivonescimab combination to enter Phase III study under new AstraZeneca, Daiichi Sankyo and Summit collaboration, Dr. Maky Zanganeh, DXd ADC Technology, EGFR, ivonescimab, John Tsai, lung cancer, New clinical collaboration will test Datroway with ivonescimab in lung, breast and other tumour types, non-small cell lung cancer, NSCLC, PD-1, Phase III, Sone-Ve, sonesitatug vedotin, Summit Therapeutics, Susan Galbraith, TNBC, triple-negative breast cancer, TROP2, TROPION-Breast01, TROPION-Breast02, TROPION-Lung01, TROPION-Lung05, VEGF
(IN BRIEF) Researchers from the University of Copenhagen and Rigshospitalet have made significant strides in developing a new treatment for pancreatic cancer using antibody-drug conjugates (ADCs). This targeted therapy promises to improve survival rates by precisely attacking cancer cells while … Read the full press release →
Posted in Business, Denmark, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged ADC, antibody-drug conjugates, cancer treatment, chemotherapy, colon cancer, Finsen Laboratory, human clinical trials, immune system, Lars Henning Engelholm, pancreatic cancer, pharmaceutical research, precision medicine, Rigshospitalet, sarcoma, Science Advances, survival rates, targeted therapy, triple-negative breast cancer, University of Copenhagen
(IN BRIEF) Researchers from the University of Freiburg have found that triple-negative breast cancer stem cells are invisible to the immune system due to changes in their metabolism. The study discovered that the cells adapt to become undetectable by downregulating … Read the full press release →
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Digi Communications NV announces availability of Digi Spain’s H1 2026 financial results presentation
Load more...
